nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC18A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0702	0.0702	CbGpPWpGaD
Methamphetamine—MAOA—Melatonin metabolism and effects—MAP2—age related macular degeneration	0.0431	0.0431	CbGpPWpGaD
Methamphetamine—SLC18A1—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.0319	0.0319	CbGpPWpGaD
Methamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0287	0.0287	CbGpPWpGaD
Methamphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0248	0.0248	CbGpPWpGaD
Methamphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0247	0.0247	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—REST—age related macular degeneration	0.0238	0.0238	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.02	0.02	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—REST—age related macular degeneration	0.0195	0.0195	CbGpPWpGaD
Methamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0193	0.0193	CbGpPWpGaD
Methamphetamine—CYP2D6—Melatonin metabolism and effects—MAP2—age related macular degeneration	0.0187	0.0187	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.0182	0.0182	CbGpPWpGaD
Methamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC16A8—age related macular degeneration	0.0171	0.0171	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.0162	0.0162	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.0162	0.0162	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—RHO—age related macular degeneration	0.0153	0.0153	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—MAP2—age related macular degeneration	0.0137	0.0137	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.013	0.013	CbGpPWpGaD
Methamphetamine—MAOA—Melatonin metabolism and effects—APOE—age related macular degeneration	0.0126	0.0126	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.0113	0.0113	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.0112	0.0112	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—MAP2—age related macular degeneration	0.0112	0.0112	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—SERPING1—age related macular degeneration	0.0104	0.0104	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—SERPING1—age related macular degeneration	0.00971	0.00971	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.00876	0.00876	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—RHO—age related macular degeneration	0.00863	0.00863	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00801	0.00801	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—SERPING1—age related macular degeneration	0.00789	0.00789	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—RHO—age related macular degeneration	0.00784	0.00784	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.00776	0.00776	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RDH8—age related macular degeneration	0.00755	0.00755	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.00743	0.00743	CbGpPWpGaD
Methamphetamine—SLC6A4—NRF2 pathway—SQSTM1—age related macular degeneration	0.00716	0.00716	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—RHO—age related macular degeneration	0.00694	0.00694	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—CST3—age related macular degeneration	0.00681	0.00681	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00662	0.00662	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00662	0.00662	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RPE65—age related macular degeneration	0.0066	0.0066	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00648	0.00648	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—RHO—age related macular degeneration	0.00648	0.00648	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—RHO—age related macular degeneration	0.00644	0.00644	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.00642	0.00642	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.0064	0.0064	CbGpPWpGaD
Methamphetamine—SLC6A2—NRF2 pathway—SQSTM1—age related macular degeneration	0.00616	0.00616	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—RHO—age related macular degeneration	0.00601	0.00601	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00572	0.00572	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00572	0.00572	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00571	0.00571	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00571	0.00571	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—F13B—age related macular degeneration	0.0057	0.0057	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00552	0.00552	CbGpPWpGaD
Methamphetamine—CYP2D6—Melatonin metabolism and effects—APOE—age related macular degeneration	0.00551	0.00551	CbGpPWpGaD
Methamphetamine—SLC6A3—NRF2 pathway—SQSTM1—age related macular degeneration	0.00545	0.00545	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SERPING1—age related macular degeneration	0.00536	0.00536	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—F13B—age related macular degeneration	0.00532	0.00532	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ABCA4—age related macular degeneration	0.00532	0.00532	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—RHO—age related macular degeneration	0.00526	0.00526	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00515	0.00515	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00507	0.00507	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SERPING1—age related macular degeneration	0.005	0.005	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.005	0.005	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—C3—age related macular degeneration	0.00494	0.00494	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—RHO—age related macular degeneration	0.00489	0.00489	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RAD51B—age related macular degeneration	0.00465	0.00465	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RHO—age related macular degeneration	0.00463	0.00463	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—NMNAT1—age related macular degeneration	0.0045	0.0045	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00445	0.00445	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00445	0.00445	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.00443	0.00443	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RAD51B—age related macular degeneration	0.00434	0.00434	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—F13B—age related macular degeneration	0.00432	0.00432	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SLC16A8—age related macular degeneration	0.00432	0.00432	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—RHO—age related macular degeneration	0.0042	0.0042	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00419	0.00419	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SERPING1—age related macular degeneration	0.00406	0.00406	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SLC16A8—age related macular degeneration	0.00403	0.00403	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00395	0.00395	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00395	0.00395	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ELOVL4—age related macular degeneration	0.00393	0.00393	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—RHO—age related macular degeneration	0.00392	0.00392	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—CCL2—age related macular degeneration	0.00386	0.00386	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NMNAT1—age related macular degeneration	0.00381	0.00381	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RAD51B—age related macular degeneration	0.00352	0.00352	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ELOVL4—age related macular degeneration	0.00333	0.00333	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SLC16A8—age related macular degeneration	0.00328	0.00328	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00327	0.00327	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—RHO—age related macular degeneration	0.00319	0.00319	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—SLC16A8—age related macular degeneration	0.00317	0.00317	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00283	0.00283	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NMNAT1—age related macular degeneration	0.00282	0.00282	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00282	0.00282	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—C3—age related macular degeneration	0.00279	0.00279	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—SLC16A8—age related macular degeneration	0.00268	0.00268	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TGFBR1—age related macular degeneration	0.0026	0.0026	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—C3—age related macular degeneration	0.00253	0.00253	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.00249	0.00249	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ELOVL4—age related macular degeneration	0.00247	0.00247	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—RHO—age related macular degeneration	0.00237	0.00237	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SQSTM1—age related macular degeneration	0.00236	0.00236	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.00232	0.00232	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NMNAT1—age related macular degeneration	0.00232	0.00232	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—C3—age related macular degeneration	0.00224	0.00224	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—RHO—age related macular degeneration	0.00222	0.00222	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.0022	0.0022	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	0.00217	0.00217	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—RHO—age related macular degeneration	0.00216	0.00216	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—C3—age related macular degeneration	0.0021	0.0021	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RDH8—age related macular degeneration	0.00208	0.00208	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ELOVL4—age related macular degeneration	0.00203	0.00203	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—RHO—age related macular degeneration	0.00201	0.00201	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—SLC16A8—age related macular degeneration	0.00199	0.00199	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCL2—age related macular degeneration	0.00198	0.00198	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00195	0.00195	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RDH8—age related macular degeneration	0.00194	0.00194	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.00189	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NMNAT1—age related macular degeneration	0.00189	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RPE65—age related macular degeneration	0.00182	0.00182	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—RHO—age related macular degeneration	0.0018	0.0018	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00178	0.00178	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	0.00178	0.00178	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—C3—age related macular degeneration	0.0017	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RPE65—age related macular degeneration	0.0017	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00167	0.00167	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ELOVL4—age related macular degeneration	0.00165	0.00165	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RHO—age related macular degeneration	0.00164	0.00164	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SLC16A8—age related macular degeneration	0.00164	0.00164	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—LIPC—age related macular degeneration	0.00162	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RDH8—age related macular degeneration	0.00158	0.00158	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CETP—age related macular degeneration	0.00156	0.00156	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—C3—age related macular degeneration	0.0015	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ABCA4—age related macular degeneration	0.00146	0.00146	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.0014	0.0014	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—APOE—age related macular degeneration	0.00139	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RPE65—age related macular degeneration	0.00138	0.00138	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—LIPC—age related macular degeneration	0.00137	0.00137	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ABCA4—age related macular degeneration	0.00137	0.00137	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—KDR—age related macular degeneration	0.00136	0.00136	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—C3—age related macular degeneration	0.00136	0.00136	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00135	0.00135	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SLC16A8—age related macular degeneration	0.00133	0.00133	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CETP—age related macular degeneration	0.00132	0.00132	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.0013	0.0013	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—CD36—age related macular degeneration	0.00128	0.00128	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RHO—age related macular degeneration	0.00127	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—C3—age related macular degeneration	0.00127	0.00127	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NMNAT1—age related macular degeneration	0.00123	0.00123	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—CD36—age related macular degeneration	0.0012	0.0012	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RHO—age related macular degeneration	0.00119	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.00118	0.00118	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL2—age related macular degeneration	0.00117	0.00117	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ABCA4—age related macular degeneration	0.00111	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.00111	0.00111	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ELOVL4—age related macular degeneration	0.00107	0.00107	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL2—age related macular degeneration	0.00106	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00106	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—C3—age related macular degeneration	0.00103	0.00103	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—LIPC—age related macular degeneration	0.00102	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL2—age related macular degeneration	0.000993	0.000993	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CETP—age related macular degeneration	0.000982	0.000982	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—CD36—age related macular degeneration	0.000973	0.000973	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RHO—age related macular degeneration	0.000966	0.000966	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CD36—age related macular degeneration	0.000941	0.000941	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.000898	0.000898	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC16A8—age related macular degeneration	0.000866	0.000866	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—LIPC—age related macular degeneration	0.000837	0.000837	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—APOE—age related macular degeneration	0.00083	0.00083	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CETP—age related macular degeneration	0.000808	0.000808	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL2—age related macular degeneration	0.000806	0.000806	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CD36—age related macular degeneration	0.000796	0.000796	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—C3—age related macular degeneration	0.000768	0.000768	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—age related macular degeneration	0.000752	0.000752	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—C3—age related macular degeneration	0.000717	0.000717	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFBR1—age related macular degeneration	0.000715	0.000715	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—APOE—age related macular degeneration	0.000702	0.000702	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—C3—age related macular degeneration	0.000697	0.000697	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—LIPC—age related macular degeneration	0.00068	0.00068	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFBR1—age related macular degeneration	0.000668	0.000668	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CETP—age related macular degeneration	0.000656	0.000656	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—C3—age related macular degeneration	0.000651	0.000651	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SQSTM1—age related macular degeneration	0.000648	0.000648	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—age related macular degeneration	0.00061	0.00061	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SQSTM1—age related macular degeneration	0.000605	0.000605	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CD36—age related macular degeneration	0.00059	0.00059	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—C3—age related macular degeneration	0.000582	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—age related macular degeneration	0.00057	0.00057	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL2—age related macular degeneration	0.000545	0.000545	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFBR1—age related macular degeneration	0.000542	0.000542	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—C3—age related macular degeneration	0.000529	0.000529	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—APOE—age related macular degeneration	0.000521	0.000521	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL2—age related macular degeneration	0.00051	0.00051	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SQSTM1—age related macular degeneration	0.000492	0.000492	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CD36—age related macular degeneration	0.000485	0.000485	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—age related macular degeneration	0.000463	0.000463	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LIPC—age related macular degeneration	0.000443	0.000443	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—age related macular degeneration	0.000428	0.000428	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CETP—age related macular degeneration	0.000428	0.000428	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL2—age related macular degeneration	0.000414	0.000414	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C3—age related macular degeneration	0.000412	0.000412	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CD36—age related macular degeneration	0.000394	0.000394	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C3—age related macular degeneration	0.000385	0.000385	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—age related macular degeneration	0.000383	0.000383	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KDR—age related macular degeneration	0.000376	0.000376	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—age related macular degeneration	0.000358	0.000358	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KDR—age related macular degeneration	0.000351	0.000351	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—age related macular degeneration	0.000348	0.000348	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL2—age related macular degeneration	0.000322	0.000322	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C3—age related macular degeneration	0.000312	0.000312	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL2—age related macular degeneration	0.000301	0.000301	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—age related macular degeneration	0.000291	0.000291	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KDR—age related macular degeneration	0.000285	0.000285	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CD36—age related macular degeneration	0.000257	0.000257	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL2—age related macular degeneration	0.000244	0.000244	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—age related macular degeneration	0.000227	0.000227	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—age related macular degeneration	0.000207	0.000207	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—age related macular degeneration	0.000193	0.000193	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—age related macular degeneration	0.000157	0.000157	CbGpPWpGaD
